Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 16Squamous Cell Carcinoma of Head and Neck 11Esophageal Squamous Cell Carcinoma 11Esophageal Neoplasms 9Head and Neck Neoplasms 8Uterine Cervical Neoplasms 7Pancreatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Pancreatic cancer, adult 2Neoplasms 2Nasopharyngeal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Anal Canal 1Solid Tumors 1Solid Tumor 1Resectable Pancreatic Cancer 1Recurrence 1Penile Neoplasms 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Locally Advanced Rectal Cancer 1

Interventions

Everolimus 5Temozolomide 4sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Specimen Handling 2Sorafenib 2Octreotide 2Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1cabozantinib 1atezolizumab 1abemaciclib 1Wound Healing 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × nimotuzumab × Clear all
NCT05316480 2022-04-07

Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms

Fudan University

Phase 2 Not yet recruiting
42 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡